ClinicalTrials.gg
Not yet recruitingNCT06626217PIWATCHUpdated Oct 3, 2024

Comparison of Perfusion Index Monitoring Using a Smartwatch and a Pulse Oximeter

An interventional study of Resting conditions and Movement artifacts in Perfusion Index, sponsored by Czech Technical University in Prague. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-03.

Sponsored by Czech Technical University in Prague · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the study is to experimentally compare measured perfusion index values between smartwatch and a medical grade pulse oximeter in healthy subjects at rest and with and without motion artifacts and during exercise.

Read the detailed description

Perfusion index (PI) is one of the many vital signs monitored to assess the clinical status of a patient. PI is determined from the pulsatile part of the plethysmographic curve, with typical values measured on the fingers ranging from 0.02% to 20%. Although PI is a relatively newly measured parameter, it has already found application in many areas of clinical medicine. For example, continuous measurement of the perfusion index has been used to monitor changes in finger blood flow after finger replantation (surgical reattachment of the finger to the patient's body). As the ability to monitor the perfusion index begins to become part of the monitored parameters of smartwatches, this new feature could be used in situations where the use of finger sensors is not appropriate. However, no comparison of perfusion index measurements between smartwatch and pulse oximeter has been made to date.

02

Conditions studied

  • Perfusion Index

Keywords

  • Pulse oximetry
  • Perfusion index
  • Finger replantation
  • Smartwatch
03

In context

Lead sponsor

Czech Technical University in Prague is the lead sponsor of 36 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Adult Volunteer

Exclusion criteria

Exclusion Criteria:

  • Post-traumatic upper limb conditions affecting finger or arm perfusion
  • Injuries or diseases of the skin of the fingers and arm
  • Any acute phase of any disease
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Comparison of perfusion index monitoring using a smartwatch and a pulse oximeter

    Placing the finger pulse oximeter sensor on the left middle finger and placing the Massimo Watch W1 on the volunteer's left wrist (2 cm from the processus styloideus). Four interventions subsequently follow (Resting condition, Movement artifacts and Circulation constriction, Physical Exercise).

    Other: Resting conditions · Other: Movement artifacts · Other: Circulation constriction · Other: Physical exercise

Interventions

  • OtherResting conditions

    The volunteers hand is at rest and Perfusion index readings are taken for six minutes from pulse oximeter and smartwatch

  • OtherMovement artifacts

    The volunteer periodically spreads his/her fingers and clenches them into a fist, and Perfusion index readings are taken for six minutes from pulse oximeter and smartwatch.

  • OtherCirculation constriction

    The volunteers arm is constricted using a cuff to measure non-invasive blood pressure. The perfusion index value is monitored during the time of cuff pressure and cuff release. The measurement is followed by a 4-minute pause to allow the vascular supply to stabilize. The measurement is repeated three times.

  • OtherPhysical exercise

    The volunteer is seated on the exercise bike, rests his forearms on the handlebars and is instructed not to move his arms. The volunteer\'s heart rate is controlled to increase to 120 beats per minute. For five minutes, the perfusion index is recorded from a pulse oximeter and smartwatch.

06

What researchers measure

Primary outcomes

  1. Comparison of measured perfusion index values between pulse oximeter and smartwatch during different interventions.

    The comparison of measured perfusion index values between pulse oximeter and smartwatch during different interventions (Resting conditions, Movement artifacts, Circulation costriction and Physical exercise) will be analyzed.

    Time frame: 1 hour

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — The measured data will be shared publicly in the data repository on web page: https://ventilation.fbmi.cvut.cz/data/

Supporting information: Statistical analysis plan

Time frame: Unlimited from the time of processing complete measured data

Access criteria: Publicly available to everyone

Data sharing details ↗ · ventilation.fbmi.cvut.cz

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2024; primary completion for Apr 2025, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2024
First posted
Oct 3, 2024
StartEst.
Oct 8, 2024
Primary completionEst.
Apr 30, 2025
CompletionEst.
Aug 30, 2025
Last update
Oct 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06626217
Lead sponsor
Czech Technical University in Prague
Responsible party
Sponsor
First posted
Oct 3, 2024
Start date
Oct 8, 2024 (estimated)
Primary completion
Apr 30, 2025 (estimated)
Completion
Aug 30, 2025 (estimated)
Last update
Oct 3, 2024

Study contacts

Simon Walzel, MEng.
Contact
walzesim@fbmi.cvut.cz
420724836120
Karel Roubik, Prof.
Contact
roubik@fbmi.cvut.cz
Karel Roubik
study chair · Czech Technical University, Fac. of Biomedical Engineering

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion